Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) - BioSpace

Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)  BioSpace

Published: Jun 24, 2019. STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty ...



Comments

Popular posts from this blog

“Stem cells: A possible treatment for severe respiratory failure, a COVID-19 complication - Mirage News” plus 1 more

“Screening for hearing loss in primary care - Contemporary Pediatrics” plus 1 more

“Evidence of cross-species filovirus transmission from bats to humans - EurekAlert” plus 2 more